On Wednesday, Ascena Retail Group Inc (NASDAQ:ASNA)’s shares inclined 11.78% to $13.38.
ascena retail group, inc. (ASNA) stated financial results for its fiscal fourth quarter and full year ended July 25, 2015.
For the fourth quarter of Fiscal 2015, the Company stated a loss from ongoing operations of $1.98 per diluted share contrast to earnings from ongoing operations of $0.10 per diluted share in the same period of Fiscal 2014. The Fiscal 2015 loss primarily reflects a $306 million impairment of goodwill and an intangible asset at Lane Bryant and an about $50 million accrual for costs related to the Justice pricing lawsuits. Adjusted earnings from ongoing operations for the fourth quarter of Fiscal 2015 were $0.06 per diluted share, contrast to $0.13 per diluted share for the fourth quarter of Fiscal 2014. Reference should be made to Note 1 in the accompanying unaudited condensed merged financial information for a talk about of the “Use of Non-GAAP Financial Measures.”
For the full year Fiscal 2015, the Company stated a loss from ongoing operations of $1.46 per diluted share as a result of the charges talk about above contrast to earnings from ongoing operations of $0.84 per diluted share in the same period of Fiscal 2014. Adjusted earnings from ongoing operations for the full year Fiscal 2015 were $0.59 per diluted share, contrast to $1.00 per diluted share in the preceding year.
Ascena Retail Group, Inc., through its auxiliaries, operates as a specialty retailer of apparel for women, and tween girls and boys. It operates through five segments: Justice, Lane Bryant, maurices, dressbarn, and Catherines segments.
Visa Inc (NYSE:V)’s shares gained 0.64% to $70.96.
Chase Card Services, a division of JPMorgan Chase & Co. [JPM], Visa Inc. [V] and United Airlines [UAL] declared the extension of the popular United MileagePlus® credit card program. The multi-year agreements extend the more than 20-year legacy of providing exceptional benefits tailored for consumer and business cardmembers.
This extension will continue offering a rich credit card program across multiple products counting the United MileagePlus® Explorer, United MileagePlus® Explorer Business and United MileagePlus® Club cards. Additionally, cardmembers will continue to enjoy access to exclusive events with InsideAccess.com in addition to exclusive luxury hotel and resort privileges.
Visa Inc., a payments technology company, operates as a retail electronic payments network worldwide. The company facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
At the end of Wednesday’s trade, AK Steel Holding Corporation (NYSE:AKS)‘s shares surged 1.81% to $2.82.
AK Steel (AKS) said that it plans to release its third quarter 2015 financial results before the opening of trading on the New York Stock Exchange on Tuesday, October 27, 2015.
AK Steel Holding Corporation, through its partner, AK Steel Corporation, produces flat-rolled carbon, stainless and electrical steel, and tubular products in the United States and internationally. It produces flat-rolled value-added carbon steels, counting coated, cold-rolled, and hot-rolled carbon steel products; and specialty stainless and electrical steels in sheet and strip forms.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), ended its Wednesday’s trading session with -0.94% loss, and closed at $64.58.
Teva Pharmaceutical Industries Ltd., (TEVA) declared that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for ProAir® RespiClick (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in patients 4 to 11 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).
ProAir® RespiClick was approved by the FDA in March 2015 for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and for the prevention of EIB. ProAir® RespiClick is the only multi-dose, breath-activated short-acting beta-agonist (SABA) inhaler accessible to patients in the U.S. It differs from other presently accessible rescue inhalers as it utilizes breath-activated technology that enables patients to breathe in to receive a measured dose of the medicine, eliminating the need for hand-breath coordination during inhalation.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
